AbbVie’s Parkinson’s drug hits primary endpoint in late-stage trial By Reuters

(Reuters) – AbbVie said on Thursday its drug met the main goal in an late-stage study when it was tested in patients with early Parkinson’s disease.

The study looked at two doses of the drug, tavapadone, as monotherapy, in which patients showed statistically significant improvement compared to placebo, measured on a rating scale that assesses different aspects of the disease.

Tavapadone is being studied as a once-daily treatment for Parkinson’s disease – a movement disorder of the nervous system that gets worse over time.

AbbVie (NYSE: ) gained access to the treatment with its $8.7 billion purchase of Cerevel Therapeutics.